ProfileGDS5678 / 1420276_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 73% 72% 72% 71% 74% 70% 72% 67% 68% 72% 72% 67% 74% 73% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.6831573
GSM967853U87-EV human glioblastoma xenograft - Control 24.6215972
GSM967854U87-EV human glioblastoma xenograft - Control 34.5719172
GSM967855U87-EV human glioblastoma xenograft - Control 44.5223271
GSM967856U87-EV human glioblastoma xenograft - Control 54.9008174
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.3564770
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.5692372
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.0391467
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.1279268
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.5562972
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.6007972
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.0905767
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.846674
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.6232873